1
|
Cheng X, Wang Y, Gong G, Shen P, Li Z, Bian J. Design strategies and recent development of bioactive modulators for glutamine transporters. Drug Discov Today 2024; 29:103880. [PMID: 38216118 DOI: 10.1016/j.drudis.2024.103880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2023] [Revised: 12/25/2023] [Accepted: 01/08/2024] [Indexed: 01/14/2024]
Abstract
Glutamine transporters are integral to the metabolism of glutamine in both healthy tissues and cancerous cells, playing a pivotal role in maintaining amino acid balance, synthesizing biomolecules, and regulating redox equilibrium. Their critical functions in cellular metabolism make them promising targets for oncological therapies. Recent years have witnessed substantial progress in the field of glutamine transporters, marked by breakthroughs in understanding of their protein structures and the discovery of novel inhibitors, prodrugs, and radiotracers. This review provides a comprehensive update on the latest advancements in modulators targeting the glutamine transporter, with special attention given to LAT1 and ASCT2. It also discusses innovative approaches in drug design aimed at these transporters.
Collapse
Affiliation(s)
- Xinying Cheng
- School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China
| | - Yezhi Wang
- School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China
| | - Guangyue Gong
- School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China
| | - Pei Shen
- School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China
| | - Zhiyu Li
- School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
| | - Jinlei Bian
- School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
| |
Collapse
|
2
|
Attia SA, Truong AT, Phan A, Lee SJ, Abanmai M, Markanovic M, Avila H, Luo H, Ali A, Sreekumar PG, Kannan R, MacKay JA. αB-Crystallin Peptide Fused with Elastin-like Polypeptide: Intracellular Activity in Retinal Pigment Epithelial Cells Challenged with Oxidative Stress. Antioxidants (Basel) 2023; 12:1817. [PMID: 37891896 PMCID: PMC10604459 DOI: 10.3390/antiox12101817] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2023] [Revised: 09/19/2023] [Accepted: 09/22/2023] [Indexed: 10/29/2023] Open
Abstract
BACKGROUND Oxidative stress-induced retinal degeneration is among the main contributing factors of serious ocular pathologies that can lead to irreversible blindness. αB-crystallin (cry) is an abundant component of the visual pathway in the vitreous humor, which modulates protein and cellular homeostasis. Within this protein exists a 20 amino acid fragment (mini-cry) with both chaperone and antiapoptotic activity. This study fuses this mini-cry peptide to two temperature-sensitive elastin-like polypeptides (ELP) with the goal of prolonging its activity in the retina. METHODS The biophysical properties and chaperone activity of cry-ELPs were confirmed by mass spectrometry, cloud-point determination, and dynamic light scattering 'DLS'. For the first time, this work compares a simpler ELP architecture, cry-V96, with a previously reported ELP diblock copolymer, cry-SI. Their relative mechanisms of cellular uptake and antiapoptotic potential were tested using retinal pigment epithelial cells (ARPE-19). Oxidative stress was induced with H2O2 and comparative internalization of both cry-ELPs was made using 2D and 3D culture models. We also explored the role of lysosomal membrane permeabilization by confocal microscopy. RESULTS The results indicated successful ELP fusion, cellular association with both 2D and 3D cultures, which were enhanced by oxidative stress. Both constructs suppressed apoptotic signaling (cleaved caspase-3); however, cry-V96 exhibited greater lysosomal escape. CONCLUSIONS ELP architecture is a critical factor to optimize delivery of therapeutic peptides, such as the anti-apoptotic mini-cry peptide; furthermore, the protection of mini-cry via ELPs is enhanced by lysosomal membrane permeabilization.
Collapse
Affiliation(s)
- Sara Aly Attia
- Department of Pharmacology and Pharmaceutical Sciences, Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA; (S.A.A.); (A.T.T.); (A.P.); (M.A.); (M.M.); (H.A.); (H.L.); (A.A.)
| | - Anh Tan Truong
- Department of Pharmacology and Pharmaceutical Sciences, Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA; (S.A.A.); (A.T.T.); (A.P.); (M.A.); (M.M.); (H.A.); (H.L.); (A.A.)
| | - Alvin Phan
- Department of Pharmacology and Pharmaceutical Sciences, Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA; (S.A.A.); (A.T.T.); (A.P.); (M.A.); (M.M.); (H.A.); (H.L.); (A.A.)
| | - Shin-Jae Lee
- Mann Department of Biomedical Engineering, Viterbi School of Engineering, University of Southern California, Los Angeles, CA 90089, USA;
| | - Manal Abanmai
- Department of Pharmacology and Pharmaceutical Sciences, Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA; (S.A.A.); (A.T.T.); (A.P.); (M.A.); (M.M.); (H.A.); (H.L.); (A.A.)
- Department of Pharmaceutics, College of Pharmacy, Prince Sattam bin Abdulaziz University, Al Kharj 11942, Saudi Arabia
| | - Marinella Markanovic
- Department of Pharmacology and Pharmaceutical Sciences, Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA; (S.A.A.); (A.T.T.); (A.P.); (M.A.); (M.M.); (H.A.); (H.L.); (A.A.)
| | - Hugo Avila
- Department of Pharmacology and Pharmaceutical Sciences, Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA; (S.A.A.); (A.T.T.); (A.P.); (M.A.); (M.M.); (H.A.); (H.L.); (A.A.)
| | - Haozhong Luo
- Department of Pharmacology and Pharmaceutical Sciences, Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA; (S.A.A.); (A.T.T.); (A.P.); (M.A.); (M.M.); (H.A.); (H.L.); (A.A.)
| | - Atham Ali
- Department of Pharmacology and Pharmaceutical Sciences, Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA; (S.A.A.); (A.T.T.); (A.P.); (M.A.); (M.M.); (H.A.); (H.L.); (A.A.)
| | | | - Ram Kannan
- Doheny Eye Institute, Pasadena, CA 91103, USA; (P.G.S.); (R.K.)
- Stein Eye Institute, Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
| | - J. Andrew MacKay
- Department of Pharmacology and Pharmaceutical Sciences, Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA; (S.A.A.); (A.T.T.); (A.P.); (M.A.); (M.M.); (H.A.); (H.L.); (A.A.)
- Mann Department of Biomedical Engineering, Viterbi School of Engineering, University of Southern California, Los Angeles, CA 90089, USA;
- Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA
| |
Collapse
|
3
|
Gyimesi G, Hediger MA. Transporter-Mediated Drug Delivery. Molecules 2023; 28:molecules28031151. [PMID: 36770817 PMCID: PMC9919865 DOI: 10.3390/molecules28031151] [Citation(s) in RCA: 11] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2022] [Revised: 01/12/2023] [Accepted: 01/18/2023] [Indexed: 01/27/2023] Open
Abstract
Transmembrane transport of small organic and inorganic molecules is one of the cornerstones of cellular metabolism. Among transmembrane transporters, solute carrier (SLC) proteins form the largest, albeit very diverse, superfamily with over 400 members. It was recognized early on that xenobiotics can directly interact with SLCs and that this interaction can fundamentally determine their efficacy, including bioavailability and intertissue distribution. Apart from the well-established prodrug strategy, the chemical ligation of transporter substrates to nanoparticles of various chemical compositions has recently been used as a means to enhance their targeting and absorption. In this review, we summarize efforts in drug design exploiting interactions with specific SLC transporters to optimize their therapeutic effects. Furthermore, we describe current and future challenges as well as new directions for the advanced development of therapeutics that target SLC transporters.
Collapse
|
4
|
Awasthi A, Kumar N, Mishra A, Ravi R, Dalal A, Shankar S, Chandra R. Noscapine-Amino Acid Conjugates Suppress the Progression of Cancer Cells. ACS Pharmacol Transl Sci 2022; 5:1292-1304. [PMID: 36524011 PMCID: PMC9745893 DOI: 10.1021/acsptsci.2c00172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2022] [Indexed: 11/16/2022]
Abstract
Lung cancer is the leading cause of cancer deaths globally; 1 in 16 people are diagnosed with lung cancer in their lifetime. Microtubules, a critical cytoskeletal assembly, have an essential role in cell division. Interference with the microtubule assembly leads to genetic instability during mitosis and cancer cell death. Currently, available antimitotic drugs such as vincas and taxanes are limited due to side effects such as alopecia, myelosuppression, and drug resistance. Noscapine, an opium alkaloid, is a tubulin-binding agent and can alter the microtubule assembly, causing cancer cell death. Amino acids are fundamental building blocks for protein synthesis, making them essential for the biosynthesis of cancer cells. However, the ability of amino acids in drug transportation has yet to be exploited in developing noscapine analogues as a potential drug candidate for cancer. Hence, in the present study, we have explored the ninth position of noscapine by introducing a hydroxymethylene group using the Blanc reaction and further coupled it with a series of amino acids to construct five target conjugates in good yields. The synthesized amino acid conjugate molecules were biologically evaluated against the A549 lung cancer cell line, among which the noscapine-tryptophan conjugate showed IC50 = 32 μM, as compared to noscapine alone (IC50 = 73 μM). Morphological changes in cancer cells, cell cycle arrest in the G1 phase, and ethidium bromide/acridine orange staining indicated promising anticancer properties. Molecular docking confirmed strong binding to tubulin, with a score of -41.47 kJ/mol with all 3D coordinates and significant involvement of molecular forces, including the hydrogen bonds and hydrophobic interactions. Molecular dynamics simulations demonstrated a stable binding of noscapine-tryptophan conjugate for a prolonged time (100 ns) with the involvement of free energy through the reaction coordinates analyses, solving the bioavailability of parent noscapine to the body.
Collapse
Affiliation(s)
- Amardeep Awasthi
- Department of Chemistry, University of Delhi, Delhi-110007, India
| | - Neeraj Kumar
- Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois60611, United States
| | - Abhijeet Mishra
- Department of Biochemistry, Shivaji College, University of Delhi, Delhi-110027, India
| | - Rangnath Ravi
- Department of Chemistry, Shivaji College, University of Delhi, Delhi-110027, India
| | - Anu Dalal
- Department of Chemistry, Indian Institute of Technology, Delhi, Delhi-110016, India
| | - Saurav Shankar
- Department of Chemistry, University of Delhi, Delhi-110007, India
| | - Ramesh Chandra
- Department of Chemistry, University of Delhi, Delhi-110007, India
- Dr. B. R. Ambedkar Centre for Biomedical Research, University of Delhi, Delhi-110007, India
- Institute of Nano Medical Sciences, University of Delhi, Delhi-110007, India
| |
Collapse
|
5
|
Pandit B, Royzen M. Recent Development of Prodrugs of Gemcitabine. Genes (Basel) 2022; 13:genes13030466. [PMID: 35328020 PMCID: PMC8954202 DOI: 10.3390/genes13030466] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2022] [Revised: 02/25/2022] [Accepted: 03/01/2022] [Indexed: 12/28/2022] Open
Abstract
Gemcitabine is a nucleoside analog that has been used widely as an anticancer drug for the treatment of a variety of conditions, including ovarian, bladder, non-small-cell lung, pancreatic, and breast cancer. However, enzymatic deamination, fast systemic clearance, and the emergence of chemoresistance have limited its efficacy. Different prodrug strategies have been explored in recent years, seeking to obtain better pharmacokinetic properties, efficacy, and safety. Different drug delivery strategies have also been employed, seeking to transform gemcitabine into a targeted medicine. This review will provide an overview of the recent developments in gemcitabine prodrugs and their effectiveness in treating cancerous tumors.
Collapse
|
6
|
Wang Y, Qin L, Chen W, Chen Q, Sun J, Wang G. Novel strategies to improve tumour therapy by targeting the proteins MCT1, MCT4 and LAT1. Eur J Med Chem 2021; 226:113806. [PMID: 34517305 DOI: 10.1016/j.ejmech.2021.113806] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2021] [Revised: 08/22/2021] [Accepted: 08/24/2021] [Indexed: 02/08/2023]
Abstract
Poor selectivity, potential systemic toxicity and drug resistance are the main challenges associated with chemotherapeutic drugs. MCT1 and MCT4 and LAT1 play vital roles in tumour metabolism and growth by taking up nutrients and are thus potential targets for tumour therapy. An increasing number of studies have shown the feasibility of including these transporters as components of tumour-targeting therapy. Here, we summarize the recent progress in MCT1-, MCT4-and LAT1-based therapeutic strategies. First, protein structures, expression, relationships with cancer, and substrate characteristics are introduced. Then, different drug targeting and delivery strategies using these proteins have been reviewed, including designing protein inhibitors, prodrugs and nanoparticles. Finally, a dual targeted strategy is discussed because these proteins exert a synergistic effect on tumour proliferation. This article concentrates on tumour treatments targeting MCT1, MCT4 and LAT1 and delivery techniques for improving the antitumour effect. These innovative tactics represent current state-of-the-art developments in transporter-based antitumour drugs.
Collapse
Affiliation(s)
- Yang Wang
- Personnel Department, Guang Xi University of Chinese Medicine, Nanning, 530200, PR China
| | - Liuxin Qin
- School of Pharmacy, Guang Xi University of Chinese Medicine, Nanning, 530200, PR China
| | - Weiwei Chen
- School of Pharmacy, Guang Xi University of Chinese Medicine, Nanning, 530200, PR China
| | - Qing Chen
- Zhuang Yao Medicine Center of Engineering and Technology, Guang Xi University of Chinese Medicine, Nanning, 530200, PR China
| | - Jin Sun
- Key Laboratory of Structure-Based Drug Design and Discovery, Shenyang Pharmaceutical University, Ministry of Education, China
| | - Gang Wang
- Zhuang Yao Medicine Center of Engineering and Technology, Guang Xi University of Chinese Medicine, Nanning, 530200, PR China.
| |
Collapse
|
7
|
Bongioanni A, Bueno MS, Mezzano BA, Longhi MR, Garnero C. Amino acids and its pharmaceutical applications: A mini review. Int J Pharm 2021; 613:121375. [PMID: 34906648 DOI: 10.1016/j.ijpharm.2021.121375] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2021] [Revised: 12/03/2021] [Accepted: 12/08/2021] [Indexed: 11/30/2022]
Abstract
Amino acids are natural compounds that can be safely used in pharmaceutical applications. Considering the great interest in the amino acids used in the pharmaceutical industry, this article presents an overview of investigations reported in recent years. In this regard, the first sections begin with an introductory description of the properties, classification and safety of amino acids, while in the other sections the most common methods for the preparation of amino acids formulations and their application on solubilization, permeation and stabilization of several active pharmaceutical ingredients are described. Furthermore, available data about the multicomponent systems approach is included. Lastly, the impact of amino acids formulations on therapeutic efficacy is explored. The advantages illustrated suggest that amino acids are capable of improving the biopharmaceutical properties of drugs.
Collapse
Affiliation(s)
- Agustina Bongioanni
- Unidad de Investigación y Desarrollo en Tecnología Farmacéutica, UNITEFA-CONICET, Departamento de Ciencias Farmacéuticas, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Cordoba X5000HUA, Argentina.
| | - Maria Soledad Bueno
- Unidad de Investigación y Desarrollo en Tecnología Farmacéutica, UNITEFA-CONICET, Departamento de Ciencias Farmacéuticas, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Cordoba X5000HUA, Argentina.
| | - Belén Alejandra Mezzano
- Unidad de Investigación y Desarrollo en Tecnología Farmacéutica, UNITEFA-CONICET, Departamento de Ciencias Farmacéuticas, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Cordoba X5000HUA, Argentina.
| | - Marcela Raquel Longhi
- Unidad de Investigación y Desarrollo en Tecnología Farmacéutica, UNITEFA-CONICET, Departamento de Ciencias Farmacéuticas, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Cordoba X5000HUA, Argentina.
| | - Claudia Garnero
- Unidad de Investigación y Desarrollo en Tecnología Farmacéutica, UNITEFA-CONICET, Departamento de Ciencias Farmacéuticas, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Cordoba X5000HUA, Argentina.
| |
Collapse
|
8
|
Scalise M, Pochini L, Galluccio M, Console L, Indiveri C. Glutamine transporters as pharmacological targets: From function to drug design. Asian J Pharm Sci 2020; 15:207-219. [PMID: 32373200 PMCID: PMC7193454 DOI: 10.1016/j.ajps.2020.02.005] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2019] [Revised: 02/18/2020] [Accepted: 02/29/2020] [Indexed: 12/17/2022] Open
Abstract
Among the different targets of administered drugs, there are membrane transporters that play also a role in drug delivery and disposition. Moreover, drug-transporter interactions are responsible for off-target effects of drugs underlying their toxicity. The improvement of the drug design process is subjected to the identification of those membrane transporters mostly relevant for drug absorption, delivery and side effect production. A peculiar group of proteins with great relevance to pharmacology is constituted by the membrane transporters responsible for managing glutamine traffic in different body districts. The interest around glutamine metabolism lies in its physio-pathological role; glutamine is considered a conditionally essential amino acid because highly proliferative cells have an increased request of glutamine that cannot be satisfied only by endogenous synthesis. Then, glutamine transporters provide cells with this special nutrient. Among the glutamine transporters, SLC1A5, SLC6A14, SLC6A19, SLC7A5, SLC7A8 and some members of SLC38 family are the best characterized, so far, in both physiological and pathological conditions. Few 3D structures have been solved by CryoEM; other structural data on these transporters have been obtained by computational analysis. Interactions with drugs have been described for several transporters of this group. For some of them, the studies are at an advanced stage, for others, the studies are still in nuce and novel biochemical findings open intriguing perspectives.
Collapse
Affiliation(s)
- Mariafrancesca Scalise
- Department of DiBEST (Biologia, Ecologia e Scienze della Terra), University of Calabria, Arcavacata di Rende (CS) 87036, Italy
| | - Lorena Pochini
- Department of DiBEST (Biologia, Ecologia e Scienze della Terra), University of Calabria, Arcavacata di Rende (CS) 87036, Italy
| | - Michele Galluccio
- Department of DiBEST (Biologia, Ecologia e Scienze della Terra), University of Calabria, Arcavacata di Rende (CS) 87036, Italy
| | - Lara Console
- Department of DiBEST (Biologia, Ecologia e Scienze della Terra), University of Calabria, Arcavacata di Rende (CS) 87036, Italy
| | - Cesare Indiveri
- Department of DiBEST (Biologia, Ecologia e Scienze della Terra), University of Calabria, Arcavacata di Rende (CS) 87036, Italy
| |
Collapse
|
9
|
Zhang L, Sui C, Yang W, Luo Q. Amino acid transporters: Emerging roles in drug delivery for tumor-targeting therapy. Asian J Pharm Sci 2020; 15:192-206. [PMID: 32373199 PMCID: PMC7193455 DOI: 10.1016/j.ajps.2019.12.002] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2019] [Revised: 11/22/2019] [Accepted: 12/22/2019] [Indexed: 12/16/2022] Open
Abstract
Amino acid transporters, which play a vital role in transporting amino acids for the biosynthesis of mammalian cells, are highly expressed in types of tumors. Increasing studies have shown the feasibility of amino acid transporters as a component of tumor-targeting therapy. In this review, we focus on tumor-related amino acid transporters and their potential use in tumor-targeting therapy. Firstly, the expression characteristics of amino acid transporters in cancer and their relationship with tumor growth are reviewed. Secondly, the recognition requirements are discussed, focusing on the "acid-base" properties, conformational isomerism and structural analogues. Finally, recent developments in amino acid transporter-targeting drug delivery strategies are highlighted, including prodrugs and nanocarriers, with special attention to the latest findings of molecular mechanisms and targeting efficiency of transporter-mediated endocytosis. We aim to offer related clues that might lead to valuable tumor-targeting strategies by the utilization of amino acid transporters.
Collapse
Affiliation(s)
- Ling Zhang
- Department of Biotherapy, The First Affiliated Hospital of China Medical University, Shenyang 110001, China
| | - Chengguang Sui
- Department of Biotherapy, The First Affiliated Hospital of China Medical University, Shenyang 110001, China
| | - Wenhan Yang
- Department of Pharmacy, The First Affiliated Hospital of China Medical University, Shenyang 110001, China
- Department of Pharmacy, China Medical University, Shenyang 110001, China
| | - Qiuhua Luo
- Department of Pharmacy, The First Affiliated Hospital of China Medical University, Shenyang 110001, China
- Department of Pharmacy, China Medical University, Shenyang 110001, China
| |
Collapse
|
10
|
Liu S, Hu Z, Zhang Q, Zhu Q, Chen Y, Lu W. Co-Prodrugs of 7-Ethyl-10-hydroxycamptothecin and Vorinostat with in Vitro Hydrolysis and Anticancer Effects. ACS OMEGA 2020; 5:350-357. [PMID: 31956782 PMCID: PMC6964270 DOI: 10.1021/acsomega.9b02786] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/28/2019] [Accepted: 12/10/2019] [Indexed: 05/17/2023]
Abstract
7-Ethyl-10-hydroxycamptothecin (SN38) and vorinostat (SAHA) are quite promising combination therapy agents applied to the clinical treatment of cancer. In this study, we designed and synthesized a series of novel SN38-SAHA co-prodrugs, which were conjugated by four different amino acids including glycine, alanine, aminobutyric acid, and 6-aminocaproic acid. The hydrolytic reconversion rate to SN38 and SAHA critically depended on the carbon chain length, which were evaluated in PBS (pH 6.0/7.4) and plasma (human/mouse). With decreasing amino acid chain length, the hydrolytic reconversion rate increased gradually. The in vitro cytotoxicity test was evaluated by the sulforhodamine B (SRB) assay on the human lung adenocarcinoma cell line A549 and human colorectal cancer cell line HCT116. With the evaluation of stability and in vitro cytotoxicity, an appropriate linker was found, and the active drug can be released efficiently from compound 3a, which exhibited strong antiproliferative activity in A549 and HCT-116 cell lines correspondingly. These results indicated that the well-designed co-prodrug 3a and this kind of strategy can be a promising approach for anticancer therapy.
Collapse
Affiliation(s)
- Shuangxi Liu
- Shanghai
Engineering Research Center of Molecular Therapeutics and New Drug
Development, School of Chemistry and Molecular Engineering, East China Normal University, 3663 North Zhongshan Road, Shanghai 200062, P. R. China
| | - Zonglong Hu
- Division
of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy
of Sciences, Shanghai 201203, P. R. China
- University
of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, P. R. China
| | - Qiumeng Zhang
- Shanghai
Engineering Research Center of Molecular Therapeutics and New Drug
Development, School of Chemistry and Molecular Engineering, East China Normal University, 3663 North Zhongshan Road, Shanghai 200062, P. R. China
- Division
of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy
of Sciences, Shanghai 201203, P. R. China
- E-mail: . Tel: +86-21- 62238771 (Q.Z.)
| | - Qiwen Zhu
- Shanghai
Engineering Research Center of Molecular Therapeutics and New Drug
Development, School of Chemistry and Molecular Engineering, East China Normal University, 3663 North Zhongshan Road, Shanghai 200062, P. R. China
| | - Yi Chen
- Division
of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy
of Sciences, Shanghai 201203, P. R. China
- E-mail: . Tel: +86-21- 50801552 (Y.C.)
| | - Wei Lu
- Shanghai
Engineering Research Center of Molecular Therapeutics and New Drug
Development, School of Chemistry and Molecular Engineering, East China Normal University, 3663 North Zhongshan Road, Shanghai 200062, P. R. China
- E-mail: . Tel: +86-21- 62238771 (W.L.)
| |
Collapse
|
11
|
Viswanathan A, Sebastianelli G, Brown K, Raunio J, Sipilä V, Yli-Harja O, Candeias NR, Kandhavelu M. In vitro anti-glioblastoma activity of L-valine derived boroxazolidones. Eur J Pharmacol 2019; 854:194-200. [PMID: 30981767 DOI: 10.1016/j.ejphar.2019.04.020] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2019] [Revised: 04/05/2019] [Accepted: 04/08/2019] [Indexed: 10/27/2022]
Abstract
In the present study, a series of L-valine derived boroxazolidones, previously synthesized and reported to have residual activity in a human epithelial cell line, have been evaluated in vitro for their anti-glioblastoma activity. A boroxazolidone derivative containing 2,4-difluorophenyl moieties (6) was found to have higher cytotoxicity than the standard drug, Temozolomide (TMZ). Compound 6 was found to exhibit dose-dependent growth inhibitory effects with an IC50 of 49 μM and 53 μM for LN229 and SNB19 cells, respectively. Additionally, 6 was assessed for its role in apoptosis, caspase 3/7 activation and oxidative stress in SNB19 and LN229 cells. SNB19 cells treated with 6 showed 45.3% apoptosis in the population, while TMZ had 24.7%. In LN229 cells, the percentage of apoptotic cells treated with compound 6 and TMZ were the same. Both 6 and TMZ induced apoptosis through the activation of caspase 3/7 in SNB19 and LN229 cells. Interestingly, 6 exhibited a higher effectivity in promoting reactive oxygen species production in LN229, while it was 6-fold less in SNB19. Boroxazolidone-treated GBM cell lines increased reactive oxygen species production, suggesting that such species may be interlinked with the observed programmed cell death. Additionally, the treatment of both GBM cell lines with 6 led to G2/M phase arrest. The magnitude of anti-GBM effect of 6 is significantly higher than the known chemotherapeutic agent TMZ. This work further demonstrates the anticancer properties of L-valine derived boroxazolidones, adding another potential derivative to the collection of promising chemotherapeutic agents for GBM treatment.
Collapse
Affiliation(s)
- Anisha Viswanathan
- Molecular Signaling Lab, Faculty of Medicine and Health Technology, Tampere University and BioMediTech, P.O. Box 553, 33101 Tampere, Finland
| | - Giulia Sebastianelli
- Molecular Signaling Lab, Faculty of Medicine and Health Technology, Tampere University and BioMediTech, P.O. Box 553, 33101 Tampere, Finland
| | - Kenna Brown
- Molecular Signaling Lab, Faculty of Medicine and Health Technology, Tampere University and BioMediTech, P.O. Box 553, 33101 Tampere, Finland
| | - Jenna Raunio
- Faculty of Engineering and Natural Sciences, Tampere University, Korkeakoulunkatu 8, 33101 Tampere, Finland
| | - Vili Sipilä
- Molecular Signaling Lab, Faculty of Medicine and Health Technology, Tampere University and BioMediTech, P.O. Box 553, 33101 Tampere, Finland
| | - Olli Yli-Harja
- Computational Systems Biology Group, Faculty of Medicine and Health Technology, Tampere University and BioMedi Tech, P.O. Box 553, 33101 Tampere, Finland; Institute for Systems Biology, 1441N 34th Street, Seattle, WA 98103-8904, USA
| | - Nuno R Candeias
- Faculty of Engineering and Natural Sciences, Tampere University, Korkeakoulunkatu 8, 33101 Tampere, Finland.
| | - Meenakshisundaram Kandhavelu
- Molecular Signaling Lab, Faculty of Medicine and Health Technology, Tampere University and BioMediTech, P.O. Box 553, 33101 Tampere, Finland.
| |
Collapse
|
12
|
Liu Z, Zhou T, Han X, Lang T, Liu S, Zhang P, Liu H, Wan K, Yu J, Zhang L, Chen L, Beuerman RW, Peng B, Zhou L, Zou L. Mathematical models of amino acid panel for assisting diagnosis of children acute leukemia. J Transl Med 2019; 17:38. [PMID: 30674317 PMCID: PMC6343345 DOI: 10.1186/s12967-019-1783-9] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2018] [Accepted: 01/11/2019] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND The altered concentrations of amino acids were found in the bone marrow or blood of leukemia patients. Metabolomics technology combining mathematical model of biomarkers could be used for assisting the diagnosis of pediatric acute leukemia (AL). METHODS The concentrations of 17 amino acids was measured by targeted liquid chromatograph-tandem mass spectrometry in periphery blood collected using dried blood spots. After evaluation, the mathematical models were further evaluated by prospective clinical validation cohort for AL diagnosis. RESULTS The concentrations of 13 in 17 amino acids were statistically different between the periphery blood dried serum dots measured by targeted LC-MS/MS. The receiver operating characteristic analysis for the models of amino acid panel showed that the area under curve for AL diagnosis were 0.848, 0.834 and 0.856 by SVM, RF and XGBoost. The Kappa values in further prospectively evaluated clinical cohort were 0.697, 0.703 and 0.789 (p > 0.05) respectively, and the accuracies for the models were 84.86%, 85.20% and 89.46% respectively with further clinical validation. CONCLUSIONS The established mathematical model is a faster, cheaper and more convenient way than conventional methods, and no significant difference on the effect of diagnosis comparing with conventional methods. The mathematical model can be clinically useful for assisting pediatric AL diagnosis.
Collapse
Affiliation(s)
- Zhidai Liu
- Clinical Center for Molecular Medicine, Children's Hospital of Chongqing Medical University, 136 Zhongshan 2 Rd, Chongqing, 400014, China.,Chinese Ministry of Science and Technology Demonstration Base for International Cooperation, Beijing, China.,The Development and Diseases Key Laboratory of Ministry of Education, Nanning, China.,The Pediatrics Key Laboratory of Chongqing Science and Technology Committee, Chongqing, China
| | - Tingting Zhou
- Department of Endocrinology and Metabolism, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
| | - Xing Han
- Clinical Center for Molecular Medicine, Children's Hospital of Chongqing Medical University, 136 Zhongshan 2 Rd, Chongqing, 400014, China.,Chinese Ministry of Science and Technology Demonstration Base for International Cooperation, Beijing, China.,The Development and Diseases Key Laboratory of Ministry of Education, Nanning, China.,The Pediatrics Key Laboratory of Chongqing Science and Technology Committee, Chongqing, China
| | - Tingyuan Lang
- Key Laboratory of Clinical Laboratory Diagnostics (Ministry of Education), College of Laboratory Medicine, Chongqing Medical University, Chongqing, China
| | - Shan Liu
- Clinical Center for Molecular Medicine, Children's Hospital of Chongqing Medical University, 136 Zhongshan 2 Rd, Chongqing, 400014, China.,Chinese Ministry of Science and Technology Demonstration Base for International Cooperation, Beijing, China.,The Development and Diseases Key Laboratory of Ministry of Education, Nanning, China.,The Pediatrics Key Laboratory of Chongqing Science and Technology Committee, Chongqing, China
| | - Penghui Zhang
- Clinical Laboratory Center, Children's Hospital of Chongqing Medical University, Chongqing, China.,Chinese Ministry of Science and Technology Demonstration Base for International Cooperation, Beijing, China.,The Development and Diseases Key Laboratory of Ministry of Education, Nanning, China.,The Pediatrics Key Laboratory of Chongqing Science and Technology Committee, Chongqing, China
| | - Haiyan Liu
- Department of Hematology, Children's Hospital of Chongqing Medical University, Chongqing, China
| | - Kexing Wan
- Clinical Center for Molecular Medicine, Children's Hospital of Chongqing Medical University, 136 Zhongshan 2 Rd, Chongqing, 400014, China.,Chinese Ministry of Science and Technology Demonstration Base for International Cooperation, Beijing, China.,The Development and Diseases Key Laboratory of Ministry of Education, Nanning, China.,The Pediatrics Key Laboratory of Chongqing Science and Technology Committee, Chongqing, China
| | - Jie Yu
- Department of Hematology, Children's Hospital of Chongqing Medical University, Chongqing, China
| | - Liang Zhang
- Department of Statistics and Applied Probability, Faculty of Science, National University of Singapore, Singapore, Singapore
| | - Liyan Chen
- Singapore Eye Research Institute, The Academia, 20 College Road, Singapore, 169856, Singapore
| | - Roger W Beuerman
- Singapore Eye Research Institute, The Academia, 20 College Road, Singapore, 169856, Singapore.,Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.,Ophthalmology and Visual Sciences Academic Clinical Research Program, Duke-NUS Graduate Medical School, Singapore, Singapore
| | - Bin Peng
- Department of Health Statistics, School of Public Health, Chongqing Medical University, Yuzhong District, Chongqing, China
| | - Lei Zhou
- Singapore Eye Research Institute, The Academia, 20 College Road, Singapore, 169856, Singapore. .,Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. .,Ophthalmology and Visual Sciences Academic Clinical Research Program, Duke-NUS Graduate Medical School, Singapore, Singapore.
| | - Lin Zou
- Clinical Center for Molecular Medicine, Children's Hospital of Chongqing Medical University, 136 Zhongshan 2 Rd, Chongqing, 400014, China. .,Chinese Ministry of Science and Technology Demonstration Base for International Cooperation, Beijing, China. .,The Development and Diseases Key Laboratory of Ministry of Education, Nanning, China. .,The Pediatrics Key Laboratory of Chongqing Science and Technology Committee, Chongqing, China.
| |
Collapse
|
13
|
Synthesis of Gemcitabine-Threonine Amide Prodrug Effective on Pancreatic Cancer Cells with Improved Pharmacokinetic Properties. Molecules 2018; 23:molecules23102608. [PMID: 30314360 PMCID: PMC6222828 DOI: 10.3390/molecules23102608] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2018] [Revised: 10/02/2018] [Accepted: 10/10/2018] [Indexed: 12/24/2022] Open
Abstract
To investigate the amino acid transporter-based prodrug anticancer strategy further, several amino acid-conjugated amide gemcitabine prodrugs were synthesized to target amino acid transporters in pancreatic cancer cells. The structures of the synthesized amino acid-conjugated prodrugs were confirmed by 1H-NMR and LC-MS. The pancreatic cancer cells, AsPC1, BxPC-3, PANC-1 and MIAPaCa-2, appeared to overexpress the amino acid transporter LAT-1 by conventional RT-PCR. Among the six amino acid derivatives of gemcitabine, threonine derivative of gemcitabine (Gem-Thr) was more effective than free gemcitabine in the pancreatic cancer cells, BxPC-3 and MIAPaCa-2, respectively, in terms of anti-cancer effects. Furthermore, Gem-Thr was metabolically stable in PBS (pH 7.4), rat plasma and liver microsomal fractions. When Gem-Thr was administered to rats at 4 mg/kg i.v., Gem-Thr was found to be successfully converted to gemcitabine via amide bond cleavage. Moreover, the Gem-Thr showed the increased systemic exposure of formed gemcitabine by 1.83-fold, compared to free gemcitabine treatment, due to the significantly decreased total clearance (0.60 vs. 4.23 mL/min/kg), indicating that the amide prodrug approach improves the metabolic stability of gemcitabine in vivo. Taken together, the amino acid transporter-targeting gemcitabine prodrug, Gem-Thr, was found to be effective on pancreatic cancer cells and to offer an efficient potential means of treating pancreatic cancer with significantly better pharmacokinetic characteristics than gemcitabine.
Collapse
|
14
|
Whang CH, Yoo E, Hur SK, Kim KS, Kim D, Jo S. A highly GSH-sensitive SN-38 prodrug with an "OFF-to-ON" fluorescence switch as a bifunctional anticancer agent. Chem Commun (Camb) 2018; 54:9031-9034. [PMID: 30047958 DOI: 10.1039/c8cc05010d] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
SN-38 (7-ethyl-10-hydroxy-camptothecin) is an active metabolite of irinotecan (CPT-11) and the most potent camptothecin analogue. In this study, 2,4-dinitrobenzene sulfonyl (DNS) was covalently conjugated as a GSH-sensitive trigger to 10'-OH of SN-38 to yield a GSH-sensitive prodrug, denoted as DNS-SN38, with virtually quenched fluorescence due to donor-excited photo-induced electron transfer (d-PeT). By investigating DNS-SN38's activation properties upon fluorescence restoration and cytotoxic potency against ovarian cancer cell lines (A2780 and m-Cherry + OCSC1-F2), its potential applicability as a useful chemotherapeutic agent was demonstrated.
Collapse
Affiliation(s)
- Chang-Hee Whang
- Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, University, MS 38655, USA.
| | - Eunsoo Yoo
- Department of Pharmaceutical Sciences, Irma Lerma Rangel College of Pharmacy, Texas A&M Health Science Center, College Station, TX 77843, USA
| | - Seong Kwon Hur
- Department of Molecular & Cellular Medicine, College of Medicine, Texas A&M Health Science Center, College Station, TX 77843, USA
| | - Kyeong Soo Kim
- Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, University, MS 38655, USA.
| | - Dongin Kim
- Department of Pharmaceutical Sciences, Irma Lerma Rangel College of Pharmacy, Texas A&M Health Science Center, College Station, TX 77843, USA
| | - Seongbong Jo
- Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, University, MS 38655, USA.
| |
Collapse
|
15
|
Washio I, Nakanishi T, Ishiguro N, Yamamura N, Tamai I. Impact of Breast Cancer Resistance Protein Expression on the In Vitro Efficacy of Anticancer Drugs in Pancreatic Cancer Cell Lines. Drug Metab Dispos 2017; 46:214-222. [PMID: 29246888 DOI: 10.1124/dmd.117.078402] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2017] [Accepted: 12/04/2017] [Indexed: 12/11/2022] Open
Abstract
Breast cancer resistance protein (BCRP) overexpression confers multidrug resistance to cancer cells, and the efficacy of anticancer drugs has been reported to be significantly affected by BCRP in cell lines transfected with BCRP or selected with drugs. It is unclear whether the in vitro efficacy of anticancer drugs is affected by endogenous BCRP, although cancer cell line panels consisting of defined tumor cell lines with endogenous BCRP have been used to screen for anticancer drugs in the pharmaceutical industry. We assessed the impact of BCRP expression on efficacy of anticancer drugs using pancreatic cancer cell lines expressing varying levels of endogenous BCRP. Pancreatic cancer cell lines were selected from the Cancer Cell Line Encyclopedia (CCLE). The EC50 of 7-ethyl-10-hydroxycamptothecin (SN-38), topotecan, and mitoxantrone decreased in the presence of a BCRP inhibitor in PANC-1 and AsPC-1 cells, which exhibit high BCRP expression. However, no significant alterations in EC50 were observed in HPAF-II, SW 1990, and MIA PaCa-2, which show moderate or low BCRP expression. The shift of EC50 of anticancer drugs with and without a BCRP inhibitor increased with an increase of BCRP mRNA expression levels; however, the shift was obvious only in cells highly expressing BCRP. Thus, the in vitro efficacy of anticancer drugs on cell proliferation may be minimally affected by BCRP in most pancreatic cancer cell lines, considering that 72% of pancreatic cancer cell lines in CCLE show moderate or low BCRP expression. The effect of BCRP should be carefully evaluated in pancreatic cell lines that highly express BCRP.
Collapse
Affiliation(s)
- Ikumi Washio
- Faculty of Pharmaceutical Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan (I.W., T.N., I.T.); and Pharmacokinetics and Non-Clinical Safety Department, Nippon Boehringer Ingelheim Co. Ltd., Kobe, Japan (I.W., N.I., N.Y.)
| | - Takeo Nakanishi
- Faculty of Pharmaceutical Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan (I.W., T.N., I.T.); and Pharmacokinetics and Non-Clinical Safety Department, Nippon Boehringer Ingelheim Co. Ltd., Kobe, Japan (I.W., N.I., N.Y.)
| | - Naoki Ishiguro
- Faculty of Pharmaceutical Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan (I.W., T.N., I.T.); and Pharmacokinetics and Non-Clinical Safety Department, Nippon Boehringer Ingelheim Co. Ltd., Kobe, Japan (I.W., N.I., N.Y.)
| | - Norio Yamamura
- Faculty of Pharmaceutical Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan (I.W., T.N., I.T.); and Pharmacokinetics and Non-Clinical Safety Department, Nippon Boehringer Ingelheim Co. Ltd., Kobe, Japan (I.W., N.I., N.Y.)
| | - Ikumi Tamai
- Faculty of Pharmaceutical Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan (I.W., T.N., I.T.); and Pharmacokinetics and Non-Clinical Safety Department, Nippon Boehringer Ingelheim Co. Ltd., Kobe, Japan (I.W., N.I., N.Y.)
| |
Collapse
|
16
|
Kellici TF, Chatziathanasiadou MV, Lee MS, Sayyad N, Geromichalou EG, Vrettos EI, Tsiailanis AD, Chi SW, Geromichalos GD, Mavromoustakos T, Tzakos AG. Rational design and structure–activity relationship studies of quercetin–amino acid hybrids targeting the anti-apoptotic protein Bcl-xL. Org Biomol Chem 2017; 15:7956-7976. [DOI: 10.1039/c7ob02045g] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Anti-apoptotic proteins, like the Bcl-2 family proteins, present an important therapeutic cancer drug target.
Collapse
Affiliation(s)
- Tahsin F. Kellici
- Department of Chemistry
- University of Ioannina
- Ioannina 45110
- Greece
- Department of Chemistry
| | | | - Min-Sung Lee
- Disease Target Structure Research Center
- KRIBB
- Daejeon 34141
- Republic of Korea
| | - Nisar Sayyad
- Department of Chemistry
- University of Ioannina
- Ioannina 45110
- Greece
| | - Elena G. Geromichalou
- Laboratory of Pharmacology
- Medical School National and Kapodistrian University of Athens
- Athens 11527
- Greece
| | | | | | - Seung-Wook Chi
- Disease Target Structure Research Center
- KRIBB
- Daejeon 34141
- Republic of Korea
| | - George D. Geromichalos
- Laboratory of Inorganic Chemistry
- Faculty of Chemistry
- Aristotle University of Thessaloniki
- GR-54124 Thessaloniki
- Greece
| | | | | |
Collapse
|
17
|
Luo Q, Yang B, Tao W, Li J, Kou L, Lian H, Che X, He Z, Sun J. ATB0,+ transporter-mediated targeting delivery to human lung cancer cells via aspartate-modified docetaxel-loading stealth liposomes. Biomater Sci 2017; 5:295-304. [DOI: 10.1039/c6bm00788k] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Tumor cells have an increased demand for amino acids to support their rapid growth and malignant metastasis.
Collapse
Affiliation(s)
- Qiuhua Luo
- School of Pharmacy
- Shenyang Pharmaceutical University
- Shenyang 110016
- China
- Department of Pharmacy
| | - Bin Yang
- School of Pharmacy
- Shenyang Pharmaceutical University
- Shenyang 110016
- China
| | - Wenhui Tao
- School of Pharmacy
- Shenyang Pharmaceutical University
- Shenyang 110016
- China
| | - Jia Li
- College of life science and biological pharmacy
- Shenyang Pharmaceutical University
- Shenyang 110016
- China
| | - Longfa Kou
- School of Pharmacy
- Shenyang Pharmaceutical University
- Shenyang 110016
- China
| | - He Lian
- Department of Biomedical Engineering
- School of Medical Devices
- Shenyang Pharmaceutical University
- Shenyang
- China
| | - Xin Che
- School of Pharmacy
- Shenyang Pharmaceutical University
- Shenyang 110016
- China
| | - Zhonggui He
- School of Pharmacy
- Shenyang Pharmaceutical University
- Shenyang 110016
- China
| | - Jin Sun
- School of Pharmacy
- Shenyang Pharmaceutical University
- Shenyang 110016
- China
- Municipal Key Laboratory of Biopharmaceutics
| |
Collapse
|
18
|
Taddeo VA, Genovese S, Carlucci G, Ferrone V, Patruno A, Ferrone A, de Medina P, Fiorito S, Epifano F. Quantitative profiling of 4'-geranyloxyferulic acid and its conjugate with l-nitroarginine methyl ester in mononuclear cells by high-performance liquid chromatography with fluorescence detection. J Pharm Biomed Anal 2016; 133:49-55. [PMID: 27856101 DOI: 10.1016/j.jpba.2016.11.016] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2016] [Revised: 11/03/2016] [Accepted: 11/09/2016] [Indexed: 12/25/2022]
Abstract
Oxyprenylated natural products were shown to exert in vitro and in vivo remarkable anti-cancer and anti-inflammatory effects. This paper describes a rapid, selective, and sensitive HPLC method with fluorescence detection for determination of 4'-geranyloxyferulic acid (GOFA) and its conjugate with l-nitroarginine methyl ester (GOFA-L-NAME) in mononuclear cells. Analytes were extracted from cells using methanol and eluted on a GraceSmart RP18 analytical column (250×4.6mm i.d., 5μm particle size) kept at 25°C. A mixture of formic acid 1% in water (A) and methanol (B) were used as mobile phase, at a flow-rate of 1.2mL/min in gradient elution. A fluorescence detector (excitation/emission wavelength of 319/398nm for GOFA and GOFA-L-NAME), was used for the two analytes. Calibration curves of GOFA and GOFA-L-NAME were linear over the concentration range of 1.0-50μg/mL, with correlation coefficients (r2)≥0.9995. Intra- and inter-assay precision do not exceed 6.8%. The accuracy was from 94% to 105% for quality control samples (2.0, 25.0 and 40μg/mL). The mean (RSD%) extraction recoveries (n=5) for GOFA and GOFA-L-NAME from spiked cells at 2.0, 25.0 and 40.0μg/mL were 92.4±1.5%, 94.7±0.9% and 93.8±1.1%, for GOFA and 95.3±1.2%, 94.8±1.0% and 93.9±1.3%, for GOFA-L-NAME. The limits of detection and quantification were 0.3μg/mL and 1.0μg/mL for GOFA and GOFA-L-NAME. This method was successfully applied to measure GOFA and GOFA-L-NAME concentrations in a mononuclear cells.
Collapse
Affiliation(s)
- Vito Alessandro Taddeo
- Department of Pharmacy, University "G. d'Annunzio" - Chieti-Pescara, Via dei Vestini 31, 66100 Chieti, Italy
| | - Salvatore Genovese
- Department of Pharmacy, University "G. d'Annunzio" - Chieti-Pescara, Via dei Vestini 31, 66100 Chieti, Italy.
| | - Giuseppe Carlucci
- Department of Pharmacy, University "G. d'Annunzio" - Chieti-Pescara, Via dei Vestini 31, 66100 Chieti, Italy
| | - Vincenzo Ferrone
- Department of Pharmacy, University "G. d'Annunzio" - Chieti-Pescara, Via dei Vestini 31, 66100 Chieti, Italy
| | - Antonia Patruno
- Department of Pharmacy, University "G. d'Annunzio" - Chieti-Pescara, Via dei Vestini 31, 66100 Chieti, Italy
| | - Alessio Ferrone
- Department of Pharmacy, University "G. d'Annunzio" - Chieti-Pescara, Via dei Vestini 31, 66100 Chieti, Italy
| | | | - Serena Fiorito
- Department of Pharmacy, University "G. d'Annunzio" - Chieti-Pescara, Via dei Vestini 31, 66100 Chieti, Italy
| | - Francesco Epifano
- Department of Pharmacy, University "G. d'Annunzio" - Chieti-Pescara, Via dei Vestini 31, 66100 Chieti, Italy
| |
Collapse
|
19
|
Enhanced Cellular Uptake and Pharmacokinetic Characteristics of Doxorubicin-Valine Amide Prodrug. Molecules 2016; 21:molecules21101272. [PMID: 27669201 PMCID: PMC6274118 DOI: 10.3390/molecules21101272] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2016] [Revised: 09/09/2016] [Accepted: 09/17/2016] [Indexed: 11/17/2022] Open
Abstract
In this study, we synthesized the valine (Val)-conjugated amide prodrug of doxorubicin (DOX) by the formation of amide bonds between DOX and Val. The synthesis of the DOX-Val prodrug was identified by a proton nuclear magnetic resonance (1H-NMR) assay. In the MCF-7 cells (human breast adenocarcinoma cell; amino acid transporter–positive cell), the cellular accumulation efficiency of DOX-Val was higher than that of DOX according to the flow cytometry analysis data. Using confocal laser scanning microscopy (CLSM) imaging, it was confirmed that DOX-Val as well as DOX was mainly distributed in the nucleus of cancer cells. DOX-Val was intravenously administered to rats at a dose of 4 mg/kg, and the plasma concentrations of DOX-Val (prodrug) and DOX (formed metabolite) were quantitatively determined. Based on the systemic exposure (represented as area under the curve (AUC) values) of DOX-Val (prodrug) and DOX (formed metabolite), approximately half of DOX-Val seemed to be metabolized into DOX. However, it is expected that the remaining DOX-Val may exert improved cellular uptake efficiency in cancer cells after its delivery to the cancer region.
Collapse
|
20
|
Bala V, Rao S, Li P, Wang S, Prestidge CA. Lipophilic Prodrugs of SN38: Synthesis and in Vitro Characterization toward Oral Chemotherapy. Mol Pharm 2015; 13:287-94. [DOI: 10.1021/acs.molpharmaceut.5b00785] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Affiliation(s)
- Vaskor Bala
- School of Pharmacy and Medical
Sciences, University of South Australia, Adelaide, SA 5001, Australia
| | - Shasha Rao
- School of Pharmacy and Medical
Sciences, University of South Australia, Adelaide, SA 5001, Australia
| | - Peng Li
- School of Pharmacy and Medical
Sciences, University of South Australia, Adelaide, SA 5001, Australia
| | - Shudong Wang
- School of Pharmacy and Medical
Sciences, University of South Australia, Adelaide, SA 5001, Australia
| | - Clive A. Prestidge
- School of Pharmacy and Medical
Sciences, University of South Australia, Adelaide, SA 5001, Australia
| |
Collapse
|
21
|
The dipeptide monoester prodrugs of floxuridine and gemcitabine-feasibility of orally administrable nucleoside analogs. Pharmaceuticals (Basel) 2014; 7:169-91. [PMID: 24473270 PMCID: PMC3942691 DOI: 10.3390/ph7020169] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2013] [Revised: 01/15/2014] [Accepted: 01/22/2014] [Indexed: 12/19/2022] Open
Abstract
Dipeptide monoester prodrugs of floxuridine and gemcitabine were synthesized. Their chemical stability in buffers, enzymatic stability in cell homogenates, permeability in mouse intestinal membrane along with drug concentration in mouse plasma, and anti-proliferative activity in cancer cells were determined and compared to their parent drugs. Floxuridine prodrug was more enzymatically stable than floxuridine and the degradation from prodrug to parent drug works as the rate-limiting step. On the other hand, gemcitabine prodrug was less enzymatically stable than gemcitabine. Those dipeptide monoester prodrugs exhibited 2.4- to 48.7-fold higher uptake than their parent drugs in Caco-2, Panc-1, and AsPC-1 cells. Floxuridine and gemcitabine prodrugs showed superior permeability in mouse jejunum to their parent drugs and exhibited the higher drug concentration in plasma after in situ mouse perfusion. Cell proliferation assays in ductal pancreatic cancer cells, AsPC-1 and Panc-1, indicated that dipeptide prodrugs of floxuridine and gemcitabine were more potent than their parent drugs. The enhanced potency of nucleoside analogs was attributed to their improved membrane permeability. The prodrug forms of 5′-l-phenylalanyl-l-tyrosyl-floxuridine and 5′-l-phenylalanyl-l-tyrosyl-gemcitabine appeared in mouse plasma after the permeation of intestinal membrane and the first-pass effect, suggesting their potential for the development of oral dosage form for anti-cancer agents.
Collapse
|
22
|
Maeng HJ, Kim ES, Chough C, Joung M, Lim JW, Shim CK, Shim WS. Addition of amino acid moieties to lapatinib increases the anti-cancer effect via amino acid transporters. Biopharm Drug Dispos 2013; 35:60-9. [DOI: 10.1002/bdd.1872] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2013] [Revised: 09/12/2013] [Accepted: 10/11/2013] [Indexed: 12/17/2022]
Affiliation(s)
- Han-Joo Maeng
- College of Pharmacy; Inje University; 607 Obang-dong Gimhae Gyeongnam South Korea
| | - Eun-Seo Kim
- Department of Pharmaceutics, College of Pharmacy; Seoul National University; Seoul South Korea
| | - Chieyeon Chough
- Research and Development Center; Yangji Chemical Co. Ltd; Suwon 443-766 Korea
| | - Misuk Joung
- Research and Development Center; Yangji Chemical Co. Ltd; Suwon 443-766 Korea
| | - Jee Woong Lim
- Research and Development Center; Yangji Chemical Co. Ltd; Suwon 443-766 Korea
| | - Chang-Koo Shim
- Department of Pharmaceutics, College of Pharmacy; Seoul National University; Seoul South Korea
| | - Won-Sik Shim
- College of Pharmacy; Gachon University; Hambakmoeiro 191, Yeonsu-gu Incheon 406-799 Korea
| |
Collapse
|
23
|
Kwak EY, Choi MK, Yang SG, Shim CK, Shim WS. Investigation into the Efficacy of Val-SN-38, a Valine-Ester Prodrug of the Anti-Cancer Agent SN-38. Biomol Ther (Seoul) 2013; 20:326-31. [PMID: 24130931 PMCID: PMC3794531 DOI: 10.4062/biomolther.2012.20.3.326] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2012] [Revised: 05/03/2012] [Accepted: 05/04/2012] [Indexed: 11/05/2022] Open
Abstract
We recently reported that Val-SN-38, a novel valine ester prodrug of SN-38, had greatly improved the intracellular accumulation of SN-38 in MCF-7 cell line, probably through enhanced uptake via amino acid transporters. In the present study, the efficacy of Val-SN-38 was further investigated both in vitro and in vivo. It was found that the in vitro cytotoxic effect of Val-SN-38 was similar to that of SN-38. Moreover, Val-SN-38 exhibited an equal potency to that of SN-38 in survival experiments in vivo. Because these results seemed to be contrary to the previous finding, further investigation was performed to find out the underlying cause of the contradiction. As only the lactone form is known to have cytotoxic activity, the proportion of lactone in Val-SN-38 and SN-38 was determined, but no differences were found. However, it turned out that Val-SN-38 had poor stability compared with SN-38, which resulted in a decrease in beneficial efficacy for Val-SN-38. Overall, the present study showed that a valine-added prodrug approach could be advantageous provided that the stability of the compound can be ensured. We believe this is a noteworthy study that unravels the discrepancy between intracellular accumulation and efficacy of valine-added prodrug.
Collapse
Affiliation(s)
- Eun-Young Kwak
- College of Pharmacy, Seoul National University, Seoul 151-742
| | | | | | | | | |
Collapse
|
24
|
Vig BS, Huttunen KM, Laine K, Rautio J. Amino acids as promoieties in prodrug design and development. Adv Drug Deliv Rev 2013; 65:1370-85. [PMID: 23099277 DOI: 10.1016/j.addr.2012.10.001] [Citation(s) in RCA: 82] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2012] [Revised: 10/07/2012] [Accepted: 10/16/2012] [Indexed: 01/18/2023]
Abstract
Prodrugs are biologically inactive agents that upon biotransformation in vivo result in active drug molecules. Since prodrugs might alter the tissue distribution, efficacy and the toxicity of the parent drug, prodrug design should be considered at the early stages of preclinical development. In this regard, natural and synthetic amino acids offer wide structural diversity and physicochemical properties. This review covers the use of amino acid prodrugs to improve poor solubility, poor permeability, sustained release, intravenous delivery, drug targeting, and metabolic stability of the parent drug. In addition, practical considerations and challenges associated with the development of amino acid prodrugs are also covered.
Collapse
|
25
|
Bala V, Rao S, Boyd BJ, Prestidge CA. Prodrug and nanomedicine approaches for the delivery of the camptothecin analogue SN38. J Control Release 2013; 172:48-61. [PMID: 23928356 DOI: 10.1016/j.jconrel.2013.07.022] [Citation(s) in RCA: 150] [Impact Index Per Article: 13.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2013] [Revised: 07/19/2013] [Accepted: 07/20/2013] [Indexed: 10/26/2022]
Abstract
SN38 (7-ethyl-10-hydroxy camptothecin) is a prominent and efficacious anticancer agent. It is poorly soluble in both water and pharmaceutically approved solvents; therefore, the direct formulation of SN38 in solution form is limited. Currently, the water soluble prodrug of SN38, irinotecan (CPT-11), is formulated as a low pH solution and is approved for chemotherapy. However, CPT-11, along with most other water-soluble prodrugs shows unpredictable inter-patient conversion to SN38 in vivo, instability in the physiological environment and variable dose-related toxicities. More recently, macromolecular prodrugs (i.e. EZN-2208, IMMU-130) and nanomedicine formulations (i.e. nanoemulsions, polymeric micelles, lipid nanocapsule/nanoparticle, and liposomes) of SN38 have been investigated for improved delivery to cancer cells and tissues. Specifically, these carriers can take advantage of the EPR effect to direct drug preferentially to tumour tissues, thereby substantially improving efficacy and minimising side effects. Furthermore, oral delivery has been shown to be possible in preclinical results using nanomedicine formulations (i.e. dendrimers, lipid nanocapsules, polymeric micelles). This review summarizes the recent advances for the delivery of SN38 with a focus on macromolecular prodrugs and nanomedicines.
Collapse
Affiliation(s)
- Vaskor Bala
- Ian Wark Research Institute, University of South Australia, Mawson Lakes, SA, Australia
| | - Shasha Rao
- Ian Wark Research Institute, University of South Australia, Mawson Lakes, SA, Australia
| | - Ben J Boyd
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus), 381 Royal Parade, Parkville, VIC, Australia
| | - Clive A Prestidge
- Ian Wark Research Institute, University of South Australia, Mawson Lakes, SA, Australia.
| |
Collapse
|
26
|
N'gompaza-Diarra J, Bettayeb K, Gresh N, Meijer L, Oumata N. Synthesis and biological evaluation of selective and potent cyclin-dependent kinase inhibitors. Eur J Med Chem 2012; 56:210-6. [DOI: 10.1016/j.ejmech.2012.08.033] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2012] [Revised: 08/21/2012] [Accepted: 08/22/2012] [Indexed: 12/21/2022]
|